(KMB) Kimberly-Clark - Ratings and Ratios
Diapers, Wipes, Tissue, Towels, Feminine Care
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.99% |
| Yield on Cost 5y | 4.52% |
| Yield CAGR 5y | 3.33% |
| Payout Consistency | 49.9% |
| Payout Ratio | 73.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 19.7% |
| Value at Risk 5%th | 30.4% |
| Relative Tail Risk | -6.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.96 |
| Alpha | -25.04 |
| CAGR/Max DD | -0.20 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.698 |
| Beta | 0.069 |
| Beta Downside | -0.004 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.81% |
| Mean DD | 9.45% |
| Median DD | 9.12% |
Description: KMB Kimberly-Clark December 03, 2025
Kimberly-Clark Corp. (KMB) is a U.S.-based consumer-goods company that designs, manufactures and markets a broad portfolio of personal-care and tissue products across three operating segments: North America, International Personal Care, and International Family Care & Professional. Its brands include Huggies, Kotex, Depend, Kleenex, Scott, Viva and others, sold through grocery, mass-merchandise, drugstore, e-commerce and professional distribution channels.
In FY 2023 the company generated roughly $20 billion in net sales, with an adjusted operating margin of about 15 % and a diluted EPS of $5.20, supporting a dividend yield near 3.5 % and a 5-year average buy-back of $1.5 billion. The North America segment contributed ~55 % of revenue, while International Personal Care and International Family Care & Professional together accounted for the remaining 45 %.
Key economic drivers for KMB include consumer demand for hygiene and health-related products, which tends to be resilient in inflationary environments, and raw-material cost exposure (e-cellulose pulp, chemicals) that can compress margins if not hedged. A sector-wide trend toward e-commerce and “direct-to-consumer” channels is accelerating, especially for premium diaper and feminine-care lines, while demographic aging supports growth in incontinence and adult-care categories.
For a deeper quantitative assessment, you may find ValueRay’s sector-adjusted valuation models useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.97b TTM) > 0 and > 6% of Revenue (6% = 1.08b TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA -2.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.87% (prev -6.06%; Δ -2.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 2.62b > Net Income 1.97b (YES >=105%, WARN >=100%) |
| Net Debt (6.62b) to EBITDA (3.37b) ratio: 1.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (333.3m) change vs 12m ago -1.16% (target <= -2.0% for YES) |
| Gross Margin 35.10% (prev 36.03%; Δ -0.93pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 106.1% (prev 117.1%; Δ -11.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.76 (EBITDA TTM 3.37b / Interest Expense TTM 260.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.66
| (A) -0.09 = (Total Current Assets 5.47b - Total Current Liabilities 7.08b) / Total Assets 16.89b |
| (B) 0.56 = Retained Earnings (Balance) 9.52b / Total Assets 16.89b |
| (C) 0.15 = EBIT TTM 2.54b / Avg Total Assets 17.03b |
| (D) 0.42 = Book Value of Equity 6.50b / Total Liabilities 15.56b |
| Total Rating: 2.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.36
| 1. Piotroski 5.50pt |
| 2. FCF Yield 6.03% |
| 3. FCF Margin 13.36% |
| 4. Debt/Equity 5.44 |
| 5. Debt/Ebitda 1.96 |
| 6. ROIC - WACC (= 12.22)% |
| 7. RoE 173.3% |
| 8. Rev. Trend -64.23% |
| 9. EPS Trend 75.16% |
What is the price of KMB shares?
Over the past week, the price has changed by -0.42%, over one month by -3.49%, over three months by -15.95% and over the past year by -20.97%.
Is KMB a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 12
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the KMB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 127.4 | 26% |
| Analysts Target Price | 127.4 | 26% |
| ValueRay Target Price | 93 | -8% |
KMB Fundamental Data Overview December 21, 2025
P/E Trailing = 17.0305
P/E Forward = 13.2275
P/S = 1.6936
P/B = 25.2931
P/EG = 6.9602
Beta = 0.26
Revenue TTM = 18.06b USD
EBIT TTM = 2.54b USD
EBITDA TTM = 3.37b USD
Long Term Debt = 6.47b USD (from longTermDebt, last quarter)
Short Term Debt = 771.0m USD (from shortTermDebt, last quarter)
Debt = 7.24b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.62b USD (from netDebt column, last quarter)
Enterprise Value = 40.03b USD (33.41b + Debt 7.24b - CCE 617.0m)
Interest Coverage Ratio = 9.76 (Ebit TTM 2.54b / Interest Expense TTM 260.0m)
FCF Yield = 6.03% (FCF TTM 2.41b / Enterprise Value 40.03b)
FCF Margin = 13.36% (FCF TTM 2.41b / Revenue TTM 18.06b)
Net Margin = 10.90% (Net Income TTM 1.97b / Revenue TTM 18.06b)
Gross Margin = 35.10% ((Revenue TTM 18.06b - Cost of Revenue TTM 11.72b) / Revenue TTM)
Gross Margin QoQ = 35.71% (prev 34.97%)
Tobins Q-Ratio = 2.37 (Enterprise Value 40.03b / Total Assets 16.89b)
Interest Expense / Debt = 0.90% (Interest Expense 65.0m / Debt 7.24b)
Taxrate = 41.89% (248.0m / 592.0m)
NOPAT = 1.47b (EBIT 2.54b * (1 - 41.89%))
Current Ratio = 0.77 (Total Current Assets 5.47b / Total Current Liabilities 7.08b)
Debt / Equity = 5.44 (Debt 7.24b / totalStockholderEquity, last quarter 1.33b)
Debt / EBITDA = 1.96 (Net Debt 6.62b / EBITDA 3.37b)
Debt / FCF = 2.75 (Net Debt 6.62b / FCF TTM 2.41b)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.66% (Net Income 1.97b / Total Assets 16.89b)
RoE = 173.3% (Net Income TTM 1.97b / Total Stockholder Equity 1.14b)
RoCE = 33.37% (EBIT 2.54b / Capital Employed (Equity 1.14b + L.T.Debt 6.47b))
RoIC = 17.46% (NOPAT 1.47b / Invested Capital 8.44b)
WACC = 5.25% (E(33.41b)/V(40.65b) * Re(6.27%) + D(7.24b)/V(40.65b) * Rd(0.90%) * (1-Tc(0.42)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.84%
[DCF Debug] Terminal Value 79.74% ; FCFE base≈2.61b ; Y1≈2.90b ; Y5≈3.79b
Fair Price DCF = 198.2 (DCF Value 65.77b / Shares Outstanding 331.9m; 5y FCF grow 12.69% → 3.0% )
EPS Correlation: 75.16 | EPS CAGR: 9.39% | SUE: 0.48 | # QB: 0
Revenue Correlation: -64.23 | Revenue CAGR: -4.77% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.04 | Chg30d=-0.001 | Revisions Net=+2 | Analysts=12
EPS next Year (2026-12-31): EPS=7.66 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+2.3% | Growth Revenue=+3.4%
Additional Sources for KMB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle